Skip to main content

Table 2 Numbers and proportions (%) of patients with seropositive rheumatoid arthritis (RA), seronegative RA and undifferentiated arthritis having used various anti-rheumatic drugs by the end of the first year after arthritis diagnosis. Also, the number of DMARD purchases by the patients during the first year after diagnosis is shown

From: First-year drug therapy of new-onset rheumatoid and undifferentiated arthritis: a nationwide register-based study

 Seropositive rheumatoid arthritis
N = 4998
Seronegative rheumatoid arthritis
N = 2340
Undifferentiated arthritis
N = 2433
p-value
Females N (%)3349 (67.0)1584 (67.7)1650 (67.8) 
Mean age at diagnosis, years (SD)58 (15)56 (17)49 (17) 
Number of DMARD purchases, median (IQR)11 (7, 16)10 (6, 14)7 (4, 11)< 0.001
Medications
 Methotrexate (MTX)4167 (83.4)1789 (76.4)1512 (62.1)< 0.001
  MTX per os3998 (80.0)1706 (72.9)1406 (57.8) 
  MTX s.c.625 (12.5)308 (13.2)310 (12.7) 
 Sulfasalazine (SSZ)2520 (50.4)1090 (46.6)1362 (56.0)< 0.001
 Hydroxychloroquine (HCQ)3603 (72.1)1357 (58.0)866 (35.6)< 0.001
 Leflunomide256 (5.1)121 (5.2)119 (4.9)0.89
 Azathioprine65 (1.3)31 (1.3)23 (0.9)0.37
 Aurathiomalate42 (0.8)12 (0.5)8 (0.3)0.023
 Auranofin4 (0.1)2 (0.1)2 (0.1)0.99
 Cyclosporine13 (0.3)10 (0.4)23 (0.9)< 0.001
 Prednisolone (PRD)3626 (72.6)1706 (72.9)1283 (52.7)< 0.001
 Self-injected biologics (all)131 (2.6)125 (5.3)76 (3.1)< 0.001
 Etanercept53 (1.1)55 (2.4)31 (1.3) 
 Adalimumab40 (0.8)48 (2.1)29 (1.2) 
 Certolizumab23 0.5)19 (0.8)12 (0.5) 
 Golimumab19 (0.4)19 (0.8)9 (0.4) 
 Abatacept8 (0.2)5 (0.2)1 (0.04) 
 Tocilizumab4 (0.1)1 (0.04)1 (0.04) 
 Ustekinumab0 (0)0 (0)1 (0.04) 
 No antirheumatic medication71 (1.4)60 (2.6)73 (3.0)< 0.001
 Only prednisolone25 (0.5)30 (1.3)24 (1.0)< 0.001